PanAd3-RSV + MVA-RSV prime-boost pediatric vaccine (GlaxoSmithKline/ReiThera)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamePanAd3-RSV + MVA-RSV prime-boost pediatric vaccine (GlaxoSmithKline/ReiThera)

Drug Alias NameRSV pediatric vaccine (GlaxoSmithKline)pediatric RSV prime-boost vaccine (GSK)recombinant viral vector vaccine (Okairos)recombinant viral vector vaccine (ReiThera)

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsRespiratory Syncytial Virus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItalyUnited Kingdom

CombinationsYes

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesReithera Srl

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesReithera Srl

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A